Onartuzumab for Gastroesophageal Adenocarcinoma
Wednesday, February 4, 2015
Manish A Shah, M.D., director of gastrointestinal oncology, spoke recently to Targeted Oncology about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma.
